RAM
NBIX icon

Resona Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Resona Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.58M Sell
38,974
-4,548
-10% -$675K 0.03% 421
2026
Q1 		$5.72M Sell
43,522
-4,884
-10% -$648K 0.03% 451
2025
Q4 		$6.87M Sell
48,406
-912
-2% -$132K 0.03% 413
2025
Q3 		$6.92M Sell
49,318
-3,230
-6% -$438K 0.03% 425
2025
Q2 		$6.6M Buy
52,548
+1,581
+3% +$181K 0.03% 435
2025
Q1 		$5.65M Buy
50,967
+1,129
+2% +$143K 0.03% 431
2024
Q4 		$6.81M Sell
49,838
-1,053
-2% -$130K 0.04% 380
2024
Q3 		$5.86M Sell
50,891
-221
-0.4% -$30.3K 0.03% 436
2024
Q2 		$7.02M Buy
51,112
+850
+2% +$117K 0.04% 366
2024
Q1 		$6.93M Buy
+50,262
New +$6.86M 0.04% 382

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Resona Asset Management's NBIX Position: Q2 2026 in Review

Resona Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 10% in Q2 2026, selling an estimated $675K and leaving 38,974 shares worth $6.58M. The position accounts for 0.03% of the portfolio, ranked #421.

Resona Asset Management first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. The position peaked at $7.02M in Q2 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Resona Asset Management held 38,974 shares of Neurocrine Biosciences worth $6.58M as of Q2 2026.
  • Resona Asset Management sold 4,548 Neurocrine Biosciences shares in Q2 2026, an estimated $675K.
  • Neurocrine Biosciences made up 0.03% of Resona Asset Management's portfolio in Q2 2026, its #421 holding.
  • Resona Asset Management first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
  • Resona Asset Management's Neurocrine Biosciences position peaked at $7.02M in Q2 2024.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Resona Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.